Channels

Thu, Oct 17 4:26am

0 Biotech And Pharma Industry

Biotech & Pharma is an industry witin the Health Care sector.

Noteworthy events last week, this week and next week.

Sun, Oct 20 - Sat, Oct 26

The best way to predict the future is to create it.
Abraham Lincoln

Earnings Annoucements
514218


Biotech And Pharma Industry

JNJ $135.17 2.33 (1.75%)
Johnson & Johnson JNJNews
NYSE: JNJ $344 Billion Large-Cap. Dow Industrial. S&P 500. Biotech & Pharma industry. 5 Year Return 36%. 1 Year Return 3%. 2019 YTD Return 6%. 2.8% dividend yield. 191 total dividend payments. Dividend Aristocrat25+ consecutive years of increasing dividends. Since Earnings 3%.

JNJ Profile

Market Cap 344 Billion
JNJ Description

Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, close to half of total revenue is generated in the United States.


Visit Website

JNJ Earnings

EPS 1.83 P/E Ratio 24.34
Previous Tue, Jul 16, 2019
Latest Tue, Oct 15, 2019 (2 days ago) Price +3.40%

JNJ Dividend

Yield 2.81% / $3.80
Ex-Date Mon, Aug 26, 2019 (52 days ago)
Pay Date Tue, Sep 10, 2019
History 191 Payments (Quarterly)

JNJ Charts

$121.00
1 Year
$148.99
Dec 24, 2018
Dec 4, 2018


MRK $84.45 0.59 (0.69%)
Merck Merck
NYSE: MRK $212 Billion Large-Cap. Dow Industrial. S&P 500. Biotech & Pharma industry. 5 Year Return 56%. 1 Year Return 17%. 2019 YTD Return 12%. 2.6% dividend yield. 136 total dividend payments. Dogs Of The Dow. Earnings in 12 days on Tue, Oct 29. (Use the Earnings tab below to add this date to your calendar.)

MRK Profile

Market Cap 212 Billion
MRK Description

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiovascular disease, asthma, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the company's sales are generated in the United States.


Visit Website

MRK Earnings

EPS 1.04 P/E Ratio 33.85
Previous Tue, Jul 30, 2019
Latest Tue, Oct 29, 2019 (In 12 days)

MRK Dividend

Yield 2.61% / $2.20
Ex-Date Fri, Sep 13, 2019 (34 days ago)
Pay Date Mon, Oct 7, 2019
History 136 Payments (Quarterly)

MRK Charts

$66.10
1 Year
$87.35
Oct 25, 2018
Aug 29, 2019


PFE $36.34 0.16 (0.44%)
Pfizer pfizer
NYSE: PFE $207 Billion Large-Cap. Dow Industrial. S&P 500. Biotech & Pharma industry. 5 Year Return 30%. 1 Year Return 17%. 2019 YTD Return 16%. 4.0% dividend yield. 136 total dividend payments. Current Ex-Date in 21 days on Thu, Nov 7. (Use the Dividend tab below to add this date to your calendar.) Thu, Nov 7. Dogs Of The Dow. Earnings in 12 days on Tue, Oct 29. (Use the Earnings tab below to add this date to your calendar.)

PFE Profile

Market Cap 207 Billion
PFE Description

Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, neuroscience drug Lyrica, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor, representing over a fifth of total company sales.


Visit Website

PFE Earnings

EPS 0.91 P/E Ratio 11.28
Previous Mon, Jul 29, 2019
Latest Tue, Oct 29, 2019 (In 12 days)

PFE Dividend

Yield 3.96% / $1.44
Ex-Date Thu, Nov 7, 2019 (In 21 days)
Pay Date Mon, Dec 2, 2019
History 136 Payments (Quarterly)

PFE Charts

52 Week Low $33.97 set on Thu, Aug 15, 2019
$33.97
1 Year
$46.47
Aug 15, 2019
Dec 4, 2018


NVO $52.29 0.18 (0.34%)
Novo Nordisk A/S novonordisk
NYSE: NVO $118 Billion Large-Cap. Biotech & Pharma industry. 5 Year Return 16%. 1 Year Return 21%. 2019 YTD Return 12%. 3.0% dividend yield. 38 total dividend payments. Paid Biannually. Earnings in 21 days on Thu, Nov 7. (Use the Earnings tab below to add this date to your calendar.)

NVO Profile

Market Cap 118 Billion
NVO Description

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, as well as oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.


Visit Website

NVO Earnings

EPS 4.03 P/E Ratio 18.42
Previous Fri, Aug 9, 2019
Latest Thu, Nov 7, 2019 (In 21 days)

NVO Dividend

Yield 3.02% / $1.58
Ex-Date Fri, Mar 22, 2019 (209 days ago)
Pay Date Tue, Apr 2, 2019
History 38 Payments (Biannual)

NVO Charts

$41.59
1 Year
$53.55
Oct 25, 2018
Sep 4, 2019


AMGN $203.21 1.45 (0.71%)
Amgen Amgen
NASDAQ: AMGN $117 Billion Large-Cap. Nasdaq 100. S&P 500. Biotech & Pharma industry. 5 Year Return 48%. 1 Year Return 0%. 2019 YTD Return 6%. 2.9% dividend yield. 33 total dividend payments. Earnings in 12 days on Tue, Oct 29. (Use the Earnings tab below to add this date to your calendar.)

AMGN Profile

Market Cap 117 Billion
AMGN Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).


Visit Website

AMGN Earnings

EPS 3.59 P/E Ratio 15.15
Previous Tue, Jul 30, 2019
Latest Tue, Oct 29, 2019 (In 12 days)

AMGN Dividend

Yield 2.85% / $5.80
Ex-Date Wed, Aug 14, 2019 (64 days ago)
Pay Date Fri, Sep 6, 2019
History 33 Payments (Quarterly)

AMGN Charts

All Time High $211.90 set on Tue, Aug 13, 2019.
$166.30
1 Year
$211.90
May 15, 2019
Aug 13, 2019


SNY $44.92 0.51 (1.15%)
Sanofi SA (ADR) sanofi
NYSE: SNY $109 Billion Large-Cap. Biotech & Pharma industry. 5 Year Return 13%. 1 Year Return 1%. 2019 YTD Return 5%. 3.9% dividend yield. 19 total dividend payments. Paid Annually. Earnings in 14 days on Thu, Oct 31. (Use the Earnings tab below to add this date to your calendar.)

SNY Profile

Market Cap 109 Billion
SNY Description

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just under 10% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of sales.


Visit Website

SNY Earnings

EPS -0.04 P/E Ratio 21.78
Previous Mon, Jul 29, 2019
Latest Thu, Oct 31, 2019 (In 14 days)

SNY Dividend

Yield 3.87% / $1.74
Ex-Date Tue, May 7, 2019 (163 days ago)
Pay Date Fri, May 31, 2019
History 19 Payments (Annually)

SNY Charts

$40.00
1 Year
$45.62
Aug 5, 2019
Nov 9, 2018


LLY $107.95 1.75 (1.60%)
Eli Lilly LillyPad
NYSE: LLY $108 Billion Large-Cap. S&P 500. Biotech & Pharma industry. 5 Year Return 71%. 1 Year Return 5%. 2019 YTD Return 6%. 2.4% dividend yield. 135 total dividend payments. Earnings in 6 days on Wed, Oct 23. (Use the Earnings tab below to add this date to your calendar.)

LLY Profile

Market Cap 108 Billion
LLY Description

Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; Taltz and Olumiant for immunology; and Cialis for erectile dysfunction.


Visit Website

LLY Earnings

EPS 1.44 P/E Ratio 40.60
Previous Tue, Jul 30, 2019
Latest Wed, Oct 23, 2019 (In 6 days)

LLY Dividend

Yield 2.39% / $2.58
Ex-Date Wed, Aug 14, 2019 (64 days ago)
Pay Date Tue, Sep 10, 2019
History 135 Payments (Quarterly)

LLY Charts

52 Week Low $104.17 set on Thu, Oct 25, 2018
$104.17
1 Year
$132.13
Oct 25, 2018
Mar 26, 2019


ABBV $74.75 0.25 (0.34%)
AbbVie abbvie
NYSE: ABBV $103 Billion Large-Cap. S&P 500. Biotech & Pharma industry. 5 Year Return 37%. 1 Year Return 17%. 2019 YTD Return 16%. 5.7% dividend yield. 28 total dividend payments. Dividend Aristocrat25+ consecutive years of increasing dividends. Earnings in 15 days on Fri, Nov 1. (Use the Earnings tab below to add this date to your calendar.) Compare ABBV vs ABT.

ABBV Profile

Market Cap 103 Billion
ABBV Description

AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents over half of the company's current profits. The company was spun off from Abbott in early 2013.


Visit Website

ABBV Earnings

EPS 0.49 P/E Ratio 22.14
Previous Fri, Jul 26, 2019
Latest Fri, Nov 1, 2019 (In 15 days)

ABBV Dividend

Yield 5.73% / $4.28
Ex-Date Fri, Oct 11, 2019 (6 days ago)
Pay Date Fri, Nov 15, 2019
History 28 Payments (Quarterly)

ABBV Charts

$62.66
1 Year
$94.98
Aug 15, 2019
Dec 4, 2018


GILD $65.35 0.05 (0.08%)
Gilead Sciences GileadSciences
NASDAQ: GILD $85 Billion Large-Cap. Nasdaq 100. S&P 500. Biotech & Pharma industry. 5 Year Return 36%. 1 Year Return 12%. 2019 YTD Return 3%. 3.5% dividend yield. 15 total dividend payments. Earnings in 7 days on Thu, Oct 24. (Use the Earnings tab below to add this date to your calendar.)

GILD Profile

Market Cap 85 Billion
GILD Description

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition boosted Gilead's exposure to cell therapy in oncology.


Visit Website

GILD Earnings

EPS 1.48 P/E Ratio 55.20
Previous Tue, Jul 30, 2019
Latest Thu, Oct 24, 2019 (In 7 days)

GILD Dividend

Yield 3.49% / $2.28
Ex-Date Thu, Dec 13, 2018 (308 days ago)
Pay Date Fri, Dec 28, 2018
History 15 Payments (Quarterly)

GILD Charts

52 Week Low $60.32 set on Wed, Dec 26, 2018
$60.32
1 Year
$76.29
Dec 26, 2018
Oct 17, 2018


BMY $51.51 0.32 (0.62%)
Bristol-Myers Squibb
NYSE: BMY $81 Billion Large-Cap. S&P 500. Biotech & Pharma industry. 5 Year Return 2%. 1 Year Return 8%. 2019 YTD Return 1%. 3.2% dividend yield. 136 total dividend payments. Earnings in 14 days on Thu, Oct 31. (Use the Earnings tab below to add this date to your calendar.)

BMY Profile

Market Cap 81 Billion
BMY Description

Bristol-Myers Squibb Co discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs.


Visit Website

BMY Earnings

EPS 0.88 P/E Ratio 15.35
Previous Thu, Jul 25, 2019
Latest Thu, Oct 31, 2019 (In 14 days)

BMY Dividend

Yield 3.18% / $1.64
Ex-Date Thu, Oct 3, 2019 (14 days ago)
Pay Date Fri, Nov 1, 2019
History 136 Payments (Quarterly)

BMY Charts

$42.48
1 Year
$59.28
Jul 23, 2019
Oct 17, 2018


CELG $100.97 0.02 (0.02%)
Celgene
NASDAQ: CELG $70 Billion Large-Cap. New 52 WEEK HIGH today. Nasdaq 100. S&P 500. Biotech & Pharma industry. 5 Year Return 10%. 1 Year Return 22%. 2019 YTD Return 52%. Earnings in 7 days on Thu, Oct 24. (Use the Earnings tab below to add this date to your calendar.)

CELG Profile

Market Cap 70 Billion
CELG Description

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.


Visit Website

CELG Earnings

EPS 2.22 P/E Ratio 17.70
Previous Tue, Jul 30, 2019
Latest Thu, Oct 24, 2019 (In 7 days)

CELG Dividend

Yield --
Ex-Date --
Pay Date --
History --

CELG Charts

$58.59
1 Year
$101.22
Dec 26, 2018
Today


ZTS $127.93 0.78 (0.61%)
Zoetis
NYSE: ZTS $58 Billion Large-Cap. S&P 500. Biotech & Pharma industry. 5 Year Return 261%. 1 Year Return 39%. 2019 YTD Return 51%. 0.5% dividend yield. 27 total dividend payments. Current Ex-Date in 4 days on Mon, Oct 21. (Use the Dividend tab below to add this date to your calendar.) Mon, Oct 21. Earnings in 21 days on Thu, Nov 7. (Use the Earnings tab below to add this date to your calendar.)

ZTS Profile

Market Cap 58 Billion
ZTS Description

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns more than 55% of total revenue from production animals (cattle, pigs, poultry, and so on), and companion animal (dogs, horses, cats) products make up the remainder. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.


Visit Website

ZTS Earnings

EPS 0.77 P/E Ratio 34.56
Previous Tue, Aug 6, 2019
Latest Thu, Nov 7, 2019 (In 21 days)

ZTS Dividend

Yield 0.51% / $0.66
Ex-Date Mon, Oct 21, 2019 (In 4 days)
Pay Date Mon, Dec 2, 2019
History 27 Payments (Quarterly)

ZTS Charts

All Time High $130.20 set on Tue, Oct 15, 2019.
$78.90
1 Year
$130.20
Dec 24, 2018
Oct 15, 2019


AGN $170.92 0.76 (0.45%)
Allergan PLC
NYSE: AGN $54 Billion Large-Cap. S&P 500. Biotech & Pharma industry. 5 Year Return 5%. 1 Year Return 10%. 2019 YTD Return 26%. 1.7% dividend yield. 11 total dividend payments. Earnings in 12 days on Tue, Oct 29. (Use the Earnings tab below to add this date to your calendar.)

AGN Profile

Market Cap 54 Billion
AGN Description

Allergan is one of the largest specialty pharmaceutical manufacturers. It specializes in aesthetics, ophthalmology, women's health, gastrointestinal, and central nervous system products. In 2016, Allergan sold its generics and distribution segments to Teva.


Visit Website

AGN Earnings

EPS -5.37 P/E Ratio 0.00
Previous Tue, Aug 6, 2019
Latest Tue, Oct 29, 2019 (In 12 days)

AGN Dividend

Yield 1.73% / $2.96
Ex-Date Mon, Aug 12, 2019 (66 days ago)
Pay Date Fri, Sep 13, 2019
History 11 Payments (Quarterly)

AGN Charts

$114.27
1 Year
$192.69
Jun 17, 2019
Oct 17, 2018


VRTX $176.09 0.05 (0.03%)
Vertex Pharmaceuticals
NASDAQ: VRTX $45 Billion Large-Cap. Nasdaq 100. S&P 500. Biotech & Pharma industry. 5 Year Return 68%. 1 Year Return 2%. 2019 YTD Return 7%. Earnings in 6 days on Wed, Oct 23. (Use the Earnings tab below to add this date to your calendar.)

VRTX Profile

Market Cap 45 Billion
VRTX Description

Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, and Symdeko for cystic fibrosis, in addition to several pipeline candidates targeting this market. Vertex's pipeline also includes therapies for cancer, pain, inflammatory diseases, influenza, and other rare diseases.


Visit Website

VRTX Earnings

EPS 1.04 P/E Ratio 20.79
Previous Wed, Jul 31, 2019
Latest Wed, Oct 23, 2019 (In 6 days)

VRTX Dividend

Yield --
Ex-Date --
Pay Date --
History --

VRTX Charts

$151.80
1 Year
$195.81
Dec 24, 2018
Jan 22, 2019


BIIB $227.72 1.66 (0.73%)
Biogen
NASDAQ: BIIB $44 Billion Large-Cap. Nasdaq 100. S&P 500. Biotech & Pharma industry. 5 Year Return 21%. 1 Year Return 31%. 2019 YTD Return 25%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 5 days on Tue, Oct 22. (Use the Earnings tab below to add this date to your calendar.)

BIIB Profile

Market Cap 44 Billion
BIIB Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.


Visit Website

BIIB Earnings

EPS 7.85 P/E Ratio 10.77
Previous Tue, Jul 23, 2019
Latest Tue, Oct 22, 2019 (In 5 days)

BIIB Dividend

Yield --
Ex-Date --
Pay Date --
History --

BIIB Charts

52 Week Low $215.78 set on Wed, Sep 4, 2019
$215.78
1 Year
$344.00
Sep 4, 2019
Jan 23, 2019


REGN $299.40 4.42 (1.45%)
Regeneron Pharmaceuticals
NASDAQ: REGN $31 Billion Large-Cap. Nasdaq 100. S&P 500. Biotech & Pharma industry. 5 Year Return 18%. 1 Year Return 24%. 2019 YTD Return 20%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 19 days on Tue, Nov 5. (Use the Earnings tab below to add this date to your calendar.)

REGN Profile

Market Cap 31 Billion
REGN Description

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis and asthma; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.


Visit Website

REGN Earnings

EPS 1.77 P/E Ratio 24.20
Previous Tue, Aug 6, 2019
Latest Tue, Nov 5, 2019 (In 19 days)

REGN Dividend

Yield --
Ex-Date --
Pay Date --
History --

REGN Charts

52 Week Low $271.37 set on Fri, Sep 27, 2019
$271.37
1 Year
$442.00
Sep 27, 2019
Mar 4, 2019


ALXN $99.51 5.30 (5.06%)
Alexion Pharmaceuticals
NASDAQ: ALXN $25 Billion Large-Cap. Nasdaq 100. S&P 500. Biotech & Pharma industry. 5 Year Return 41%. 1 Year Return 21%. 2019 YTD Return 1%. Earnings in 6 days on Wed, Oct 23. (Use the Earnings tab below to add this date to your calendar.)

ALXN Profile

Market Cap 25 Billion
ALXN Description

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis. Next-generation Ultomiris was recently approved in paroxysmal nocturnal hemoglobinuria. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need and complement-mediated disorders.


Visit Website

ALXN Earnings

EPS 2.05 P/E Ratio 392.83
Previous Wed, Jul 24, 2019
Latest Wed, Oct 23, 2019 (In 6 days)

ALXN Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALXN Charts

52 Week Low $92.56 set on Mon, Dec 24, 2018
$92.56
1 Year
$141.86
Dec 24, 2018
Apr 10, 2019


INCY $78.12 0.40 (0.51%)
Incyte
NASDAQ: INCY $17 Billion Large-Cap. Nasdaq 100. S&P 500. Biotech & Pharma industry. 5 Year Return 54%. 1 Year Return 21%. 2019 YTD Return 23%. Earnings in 12 days on Tue, Oct 29. (Use the Earnings tab below to add this date to your calendar.)

INCY Profile

Market Cap 17 Billion
INCY Description

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which Eli Lilly licenses, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including next-generation JAK inhibitor itacitinib.


Visit Website

INCY Earnings

EPS 0.49 P/E Ratio 145.02
Previous Tue, Jul 30, 2019
Latest Tue, Oct 29, 2019 (In 12 days)

INCY Dividend

Yield --
Ex-Date --
Pay Date --
History --

INCY Charts

$57.00
1 Year
$89.30
Dec 24, 2018
Jun 24, 2019


GRFS $20.39 0.20 (0.97%)
Grifols, S.A. - American Depositary Shares
NASDAQ: GRFS $14 Billion Large-Cap. Biotech & Pharma industry. 5 Year Return 28%. 1 Year Return 1%. 2019 YTD Return 13%. 2.2% dividend yield. 14 total dividend payments. Paid Biannually. Earnings in 18 days on Mon, Nov 4. (Use the Earnings tab below to add this date to your calendar.)

GRFS Profile

Market Cap 14 Billion
GRFS Description

Grifols SA is a Spain-based vertically integrated plasma derivative producer. Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 79% of sales in 2017. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics grew to almost 20% of revenue in 2014 with the acquisition of Novartis' diagnostics unit.


Visit Website

GRFS Earnings

EPS 0.25 P/E Ratio 17.40
Previous Wed, Jul 31, 2019
Latest Mon, Nov 4, 2019 (In 18 days)

GRFS Dividend

Yield 2.24% / $0.46
Ex-Date Fri, Nov 30, 2018 (321 days ago)
Pay Date Tue, Dec 11, 2018
History 14 Payments (Biannual)

GRFS Charts

$17.42
1 Year
$23.03
Dec 24, 2018
Aug 1, 2019


BMRN $67.94 0.57 (0.83%)
BioMarin Pharmaceutical
NASDAQ: BMRN $13 Billion Large-Cap. Nasdaq 100. Biotech & Pharma industry. 5 Year Return 4%. 1 Year Return 35%. 2019 YTD Return 20%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 6 days on Wed, Oct 23. (Use the Earnings tab below to add this date to your calendar.)

BMRN Profile

Market Cap 13 Billion
BMRN Description

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.


Visit Website

BMRN Earnings

EPS -0.21 P/E Ratio 0.00
Previous Thu, Aug 1, 2019
Latest Wed, Oct 23, 2019 (In 6 days)

BMRN Dividend

Yield --
Ex-Date --
Pay Date --
History --

BMRN Charts

52 Week Low $62.88 set on Wed, Oct 2, 2019
$62.88
1 Year
$106.74
Oct 2, 2019
Oct 17, 2018


MYL $18.74 0.09 (0.48%)
Mylan NV
NASDAQ: MYL $12 Billion Large-Cap. Nasdaq 100. S&P 500. Biotech & Pharma industry. 5 Year Return 63%. 1 Year Return 42%. 2019 YTD Return 33%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 18 days on Mon, Nov 4. (Use the Earnings tab below to add this date to your calendar.)

MYL Profile

Market Cap 12 Billion
MYL Description

Registered in the Netherlands, Mylan is a leading generic drugmaker, with roughly 55 manufacturing and R&D facilities. Although the company was formed in 1961, the company's position as the second- largest generic company was largely attributable to the acquisition of Matrix Laboratories and generics business of Germany-based Merck KGaA. Mylan has a portfolio of more than 7,500 generic, specialty, and over-the-counter active ingredients and medicines and is predominantly recognized for manufacturing the EpiPen (treatment for anaphylaxis), which was acquired through the Merk KGaA transaction.


Visit Website

MYL Earnings

EPS -0.33 P/E Ratio 28.88
Previous Mon, Jul 29, 2019
Latest Mon, Nov 4, 2019 (In 18 days)

MYL Dividend

Yield --
Ex-Date --
Pay Date --
History 73 Payments (Quarterly)

MYL Charts

$16.63
1 Year
$37.56
May 31, 2019
Nov 6, 2018


SGEN $83.86 0.48 (0.58%)
Seattle Genetics
NASDAQ: SGEN $11 Billion Large-Cap. Biotech & Pharma industry. 5 Year Return 138%. 1 Year Return 14%. 2019 YTD Return 46%. Earnings in 12 days on Tue, Oct 29. (Use the Earnings tab below to add this date to your calendar.)

SGEN Profile

Market Cap 11 Billion
SGEN Description

Seattle Genetics is a biotech firm focused on the development of monoclonal antibody-based therapies. The company's lead product, Adcetris, has received approval for advanced frontline, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. The company has several other early-stage programs in trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.


Visit Website

SGEN Earnings

EPS -0.49 P/E Ratio 0.00
Previous Tue, Jul 16, 2019
Latest Tue, Oct 29, 2019 (In 12 days)

SGEN Dividend

Yield --
Ex-Date --
Pay Date --
History --

SGEN Charts

All Time High $88.20 set on Mon, Sep 30, 2019.
$50.71
1 Year
$88.20
Oct 30, 2018
Sep 30, 2019


GLPG $161.68 0.51 (0.31%)
Galapagos NV - American Depositary Shares
NASDAQ: GLPG $10 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 220%. 1 Year Return 54%. 2019 YTD Return 79%. Earnings in 8 days on Fri, Oct 25. (Use the Earnings tab below to add this date to your calendar.)

GLPG Profile

Market Cap 10 Billion
GLPG Description

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.


Visit Website

GLPG Earnings

EPS -0.86 P/E Ratio 0.00
Previous Thu, Jul 25, 2019
Latest Fri, Oct 25, 2019 (In 8 days)

GLPG Dividend

Yield --
Ex-Date --
Pay Date --
History --

GLPG Charts

$85.00
1 Year
$191.63
Dec 27, 2018
Jul 22, 2019


ALNY $81.67 0.82 (1.01%)
Alnylam Pharmaceuticals Inc
NASDAQ: ALNY $10 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 7%. 1 Year Return 4%. 2019 YTD Return 12%. Earnings in 20 days on Wed, Nov 6. (Use the Earnings tab below to add this date to your calendar.)

ALNY Profile

Market Cap 10 Billion
ALNY Description

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis, Alnylam has partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.


Visit Website

ALNY Earnings

EPS -2.02 P/E Ratio 0.00
Previous Tue, Aug 6, 2019
Latest Wed, Nov 6, 2019 (In 20 days)

ALNY Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALNY Charts

$60.27
1 Year
$96.08
Dec 24, 2018
Apr 1, 2019


IONS $57.62 3.84 (6.25%)
Ionis Pharmaceuticals Inc
NASDAQ: IONS $9 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 0%. 1 Year Return 24%. 2019 YTD Return 7%. Earnings in 19 days on Tue, Nov 5. (Use the Earnings tab below to add this date to your calendar.)

IONS Profile

Market Cap 9 Billion
IONS Description

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline treats a wide variety of diseases, with an emphasis on cardiovascular, metabolic, severe, and rare diseases. Ionis sold rights to its first product, Kynamro, to Kastle Therapeutics after lackluster commercial success, but with partner Biogen brought its second drug, Spinraza for spinal muscular atrophy, to market. ATTR amyloidosis drug Tegsedi (inotersen) was approved in 2018 and cardiology drug Waylivra was approved in Europe in 2019.


Visit Website

IONS Earnings

EPS -0.01 P/E Ratio 41.01
Previous Wed, Aug 7, 2019
Latest Tue, Nov 5, 2019 (In 19 days)

IONS Dividend

Yield --
Ex-Date --
Pay Date --
History --

IONS Charts

$44.60
1 Year
$86.58
Oct 22, 2018
Apr 8, 2019


TEVA $6.95 0.02 (0.29%)
Teva Pharmaceutical Industries Ltd (ADR) ADR
NYSE: TEVA $9 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 87%. 1 Year Return 67%. 2019 YTD Return 56%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. This is clearly Downtrending. Avoid for now. Earnings in 21 days on Thu, Nov 7. (Use the Earnings tab below to add this date to your calendar.)

TEVA Profile

Market Cap 9 Billion
TEVA Description

Teva Pharmaceutical Industries Ltd is the largest generic drug manufacturer in the world with more than 60 manufacturing and R&D facilities, headquartered in Israel. The company was formed in 1901 and has a portfolio of more than 3,500 medicines--roughly one out of nine generic prescriptions in the U.S. is filled with a Teva product. The company also develops branded pharmaceuticals in the central nervous system, oncology, and respiratory categories. Teva's generic drug sales represent about half of total revenue, with branded drug and distribution revenue making up the balance. Teva is an aggressive filer to bring generic drugs to market when brand patents expire and has the most generic products pending FDA approval.


Visit Website

TEVA Earnings

EPS -0.63 P/E Ratio 0.00
Previous Wed, Aug 7, 2019
Latest Thu, Nov 7, 2019 (In 21 days)

TEVA Dividend

Yield --
Ex-Date --
Pay Date --
History 132 Payments (Quarterly)

TEVA Charts

$6.07
1 Year
$23.97
Aug 15, 2019
Nov 8, 2018


NBIX $93.75 0.26 (0.28%)
Neurocrine Biosciences Inc
NASDAQ: NBIX $9 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 470%. 1 Year Return 18%. 2019 YTD Return 34%. Earnings in 18 days on Mon, Nov 4. (Use the Earnings tab below to add this date to your calendar.)

NBIX Profile

Market Cap 9 Billion
NBIX Description

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.


Visit Website

NBIX Earnings

EPS 0.56 P/E Ratio 819.73
Previous Mon, Jul 29, 2019
Latest Mon, Nov 4, 2019 (In 18 days)

NBIX Dividend

Yield --
Ex-Date --
Pay Date --
History 132 Payments (Quarterly)

NBIX Charts

$64.72
1 Year
$116.48
Dec 12, 2018
Oct 19, 2018


BGNE $126.52 1.70 (1.36%)
BeiGene Ltd
NASDAQ: BGNE $8 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 347%. 1 Year Return 2%. 2019 YTD Return 7%. Earnings in 20 days on Wed, Nov 6. (Use the Earnings tab below to add this date to your calendar.)

BGNE Profile

Market Cap 8 Billion
BGNE Description

BeiGene Ltd is a United States based clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.


Visit Website

BGNE Earnings

EPS -1.43 P/E Ratio 0.00
Previous Thu, Aug 8, 2019
Latest Wed, Nov 6, 2019 (In 20 days)

BGNE Dividend

Yield --
Ex-Date --
Pay Date --
History --

BGNE Charts

$105.19
1 Year
$164.99
Oct 30, 2018
Dec 3, 2018


TECH $202.03 1.39 (0.69%)
Bio-Techne Corp
NASDAQ: TECH $8 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 123%. 1 Year Return 10%. 2019 YTD Return 42%. 0.6% dividend yield. 44 total dividend payments. Earnings in 12 days on Tue, Oct 29. (Use the Earnings tab below to add this date to your calendar.)

TECH Profile

Market Cap 8 Billion
TECH Description

Bio-Techne Corp is a life science manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The protein sciences division's key products (78% of sales) include proteins, antibodies, and assays as well as equipment and associated consumables for protein characterization and analysis. The remaining revenue in the diagnostics and genomics segment is roughly split between manufacturing creates controls, calibrators, and reagents for diagnostic manufacturers combined with proprietary molecular and genetic testing kits. The company is split into two reporting segments namely, Protein Sciences segment and Diagnostics and Genomics segment. The Protein Sciences segment generates maximum revenue for the company.


Visit Website

TECH Earnings

EPS 0.43 P/E Ratio 46.85
Previous Tue, Aug 6, 2019
Latest Tue, Oct 29, 2019 (In 12 days)

TECH Dividend

Yield 0.63% / $1.28
Ex-Date Thu, Aug 15, 2019 (63 days ago)
Pay Date Fri, Aug 30, 2019
History 44 Payments (Quarterly)

TECH Charts

All Time High $217.16 set on Wed, Jul 3, 2019.
$132.75
1 Year
$217.16
Dec 24, 2018
Jul 3, 2019


PRGO $53.93 0.12 (0.22%)
Perrigo Co PLC
NYSE: PRGO $8 Billion Mid-Cap. S&P 500. Biotech & Pharma industry. 5 Year Return 64%. 1 Year Return 25%. 2019 YTD Return 33%. 1.6% dividend yield. 67 total dividend payments. Earnings in 28 days on Thu, Nov 14. (Use the Earnings tab below to add this date to your calendar.)

PRGO Profile

Market Cap 8 Billion
PRGO Description

Perrigo is the largest store-brand over-the-counter pharmaceutical and infant formula manufacturer. The company operates three major segments: consumer healthcare, branded consumer healthcare, and prescription pharmaceuticals. As of mid-2018, Perrigo plans to divest the prescription segment. In the United States, Perrigo sells about 2,100 products with 9,000 stock-keeping units. Following the acquisition of Omega Pharma, approximately 30% of the company's revenue comes from outside the U.S.


Visit Website

PRGO Earnings

EPS 0.07 P/E Ratio 67.25
Previous Thu, Aug 8, 2019
Latest Thu, Nov 14, 2019 (In 28 days)

PRGO Dividend

Yield 1.56% / $0.84
Ex-Date Thu, Aug 29, 2019 (49 days ago)
Pay Date Tue, Sep 17, 2019
History 67 Payments (Quarterly)

PRGO Charts

$36.28
1 Year
$75.42
Dec 24, 2018
Nov 7, 2018


JAZZ $119.77 1.72 (1.46%)
Jazz Pharmaceuticals PLC
NASDAQ: JAZZ $7 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 21%. 1 Year Return 23%. 2019 YTD Return 4%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 19 days on Tue, Nov 5. (Use the Earnings tab below to add this date to your calendar.)

JAZZ Profile

Market Cap 7 Billion
JAZZ Description

Jazz Pharmaceuticals is an Ireland-domiciled specialty pharmaceutical firm focused primarily on treatments for orphan drug indications. Jazz's product portfolio includes lead drug Xyrem for narcolepsy, Erwinaze for acute lymphoblastic leukemia, Defitelio for severe veno-occlusive disease, and Vyxeos for acute myeloid leukemia.


Visit Website

JAZZ Earnings

EPS 4.62 P/E Ratio 17.26
Previous Tue, Aug 6, 2019
Latest Tue, Nov 5, 2019 (In 19 days)

JAZZ Dividend

Yield --
Ex-Date --
Pay Date --
History --

JAZZ Charts

52 Week Low $113.52 set on Mon, Dec 24, 2018
$113.52
1 Year
$165.66
Dec 24, 2018
Nov 2, 2018


SRPT $86.74 1.31 (1.49%)
Sarepta Therapeutics Inc
NASDAQ: SRPT $7 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 280%. 1 Year Return 38%. 2019 YTD Return 19%. Earnings in 6 days on Wed, Oct 23. (Use the Earnings tab below to add this date to your calendar.)

SRPT Profile

Market Cap 7 Billion
SRPT Description

Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.


Visit Website

SRPT Earnings

EPS -3.74 P/E Ratio 0.00
Previous Wed, Aug 7, 2019
Latest Wed, Oct 23, 2019 (In 6 days)

SRPT Dividend

Yield --
Ex-Date --
Pay Date --
History --

SRPT Charts

52 Week Low $72.05 set on Thu, Sep 26, 2019
$72.05
1 Year
$158.80
Sep 26, 2019
Jul 15, 2019


AMRN $16.05 0.19 (1.20%)
Amarin Corp PLC
NASDAQ: AMRN $6 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 1,429%. 1 Year Return 20%. 2019 YTD Return 23%. Earnings in 21 days on Thu, Nov 7. (Use the Earnings tab below to add this date to your calendar.)

AMRN Profile

Market Cap 6 Billion
AMRN Description

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its products include Vascepa. The firm has Development and Commercialization of Vascepa operating segment. It mainly operates in the United States.


Visit Website

AMRN Earnings

EPS -0.01 P/E Ratio 0.00
Previous Wed, Jul 31, 2019
Latest Thu, Nov 7, 2019 (In 21 days)

AMRN Dividend

Yield --
Ex-Date --
Pay Date --
History --

AMRN Charts

$11.78
1 Year
$23.91
Dec 24, 2018
Jul 5, 2019


ACAD $39.90 0.26 (0.65%)
ACADIA Pharmaceuticals Inc
NASDAQ: ACAD $6 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 50%. 1 Year Return 76%. 2019 YTD Return 140%. This is Uptrending. A good sign. Earnings in 19 days on Tue, Nov 5. (Use the Earnings tab below to add this date to your calendar.)

ACAD Profile

Market Cap 6 Billion
ACAD Description

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.


Visit Website

ACAD Earnings

EPS -0.38 P/E Ratio 0.00
Previous Wed, Jul 31, 2019
Latest Tue, Nov 5, 2019 (In 19 days)

ACAD Dividend

Yield --
Ex-Date --
Pay Date --
History --

ACAD Charts

$14.01
1 Year
$44.85
Dec 24, 2018
Sep 16, 2019


EXEL $16.78 0.01 (0.06%)
Exelixis Inc
NASDAQ: EXEL $6 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 917%. 1 Year Return 2%. 2019 YTD Return 16%. Earnings in 21 days on Thu, Nov 7. (Use the Earnings tab below to add this date to your calendar.)

EXEL Profile

Market Cap 6 Billion
EXEL Description

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.


Visit Website

EXEL Earnings

EPS 0.26 P/E Ratio 15.47
Previous Wed, Jul 31, 2019
Latest Thu, Nov 7, 2019 (In 21 days)

EXEL Dividend

Yield --
Ex-Date --
Pay Date --
History --

EXEL Charts

$13.42
1 Year
$25.31
Oct 29, 2018
Mar 18, 2019


BLUE $91.62 2.07 (2.31%)
bluebird bio Inc
NASDAQ: BLUE $6 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 149%. 1 Year Return 25%. 2019 YTD Return 8%. Earnings in 21 days on Thu, Nov 7. (Use the Earnings tab below to add this date to your calendar.)

BLUE Profile

Market Cap 6 Billion
BLUE Description

Bluebird Bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.


Visit Website

BLUE Earnings

EPS -3.55 P/E Ratio 0.00
Previous Thu, Aug 1, 2019
Latest Thu, Nov 7, 2019 (In 21 days)

BLUE Dividend

Yield --
Ex-Date --
Pay Date --
History --

BLUE Charts

52 Week Low $84.01 set on Thu, Oct 3, 2019
$84.01
1 Year
$163.43
Oct 3, 2019
Apr 3, 2019


MRNA $14.15 0.18 (1.26%)
Moderna Inc
NASDAQ: MRNA $5 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 24%. 1 Year Return 24%. 2019 YTD Return 8%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 20 days on Wed, Nov 6. (Use the Earnings tab below to add this date to your calendar.)

MRNA Profile

Market Cap 5 Billion
MRNA Description

Moderna Inc is engaged in creating transformative medicines based on messenger RNA, or mRNA. Its therapeutic and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. The company's approach is to use mRNA medicines to instruct a patient's own cells to produce proteins that could prevent, treat, or cure disease.


Visit Website

MRNA Earnings

EPS -0.41 P/E Ratio 0.00
Previous Wed, Aug 7, 2019
Latest Wed, Nov 6, 2019 (In 20 days)

MRNA Dividend

Yield --
Ex-Date --
Pay Date --
History --

MRNA Charts

$11.54
1 Year
$29.79
Aug 7, 2019
Apr 8, 2019


SAGE $140.81 3.45 (2.39%)
Sage Therapeutics Inc
NASDAQ: SAGE $5 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 304%. 1 Year Return 14%. 2019 YTD Return 57%. Earnings in 26 days on Tue, Nov 12. (Use the Earnings tab below to add this date to your calendar.)

SAGE Earnings

EPS -3.28 P/E Ratio 0.00
Previous Tue, Aug 6, 2019
Latest Tue, Nov 12, 2019 (In 26 days)

SAGE Dividend

Yield --
Ex-Date --
Pay Date --
History --

SAGE Charts

$79.88
1 Year
$193.56
Dec 24, 2018
Jul 12, 2019


ASND $101.08 0.36 (0.36%)
Ascendis Pharma A/S
NASDAQ: ASND $5 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 437%. 1 Year Return 53%. 2019 YTD Return 56%.

ASND Profile

Market Cap 5 Billion
ASND Description

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in the USA, Germany, and Switzerland and derives the majority of its revenue from the US.


Visit Website

ASND Earnings

EPS -1.25 P/E Ratio 0.00
Previous Wed, Aug 28, 2019
Latest Wed, Nov 27, 2019 (In 41 days)

ASND Dividend

Yield --
Ex-Date --
Pay Date --
History --

ASND Charts

$53.21
1 Year
$133.96
Nov 14, 2018
Jun 3, 2019


ARGX $114.97 1.49 (1.28%)
argenx SE - American Depositary Shares
NASDAQ: ARGX $5 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 400%. 1 Year Return 37%. 2019 YTD Return 16%.

ARGX Profile

Market Cap 5 Billion
ARGX Description

argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-113, ARGX-110, ARGX-115, ARGX-112 etc. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Luxembourg.


Visit Website

ARGX Earnings

EPS -0.08 P/E Ratio 0.00
Previous --
Latest --

ARGX Dividend

Yield --
Ex-Date --
Pay Date --
History --

ARGX Charts

$71.48
1 Year
$150.92
Oct 26, 2018
Jul 18, 2019


RGEN $77.77 1.45 (1.83%)
Repligen Corp
NASDAQ: RGEN $4 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 242%. 1 Year Return 38%. 2019 YTD Return 50%. Earnings in 21 days on Thu, Nov 7. (Use the Earnings tab below to add this date to your calendar.)

RGEN Profile

Market Cap 4 Billion
RGEN Description

Repligen Corp is a bioprocessing company that develops, produces and commercializes innovative biologic drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in the United States.


Visit Website

RGEN Earnings

EPS 0.17 P/E Ratio 119.64
Previous Thu, Aug 1, 2019
Latest Thu, Nov 7, 2019 (In 21 days)

RGEN Dividend

Yield --
Ex-Date --
Pay Date --
History --

RGEN Charts

$48.26
1 Year
$99.25
Dec 24, 2018
Aug 1, 2019


ALLK $71.33 1.36 (1.94%)
Allakos Inc
NASDAQ: ALLK $4 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 128%. 1 Year Return 68%. 2019 YTD Return 37%. Earnings in 28 days on Thu, Nov 14. (Use the Earnings tab below to add this date to your calendar.)

ALLK Profile

Market Cap 4 Billion
ALLK Description

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.


Visit Website

ALLK Earnings

EPS -0.44 P/E Ratio 0.00
Previous Mon, Aug 5, 2019
Latest Thu, Nov 14, 2019 (In 28 days)

ALLK Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALLK Charts

$30.32
1 Year
$92.84
Aug 2, 2019
Aug 7, 2019


ONCE $100.12 1.04 (1.05%)
Spark Therapeutics Inc
NASDAQ: ONCE $4 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 100%. 1 Year Return 101%. 2019 YTD Return 156%. Earnings in 19 days on Tue, Nov 5. (Use the Earnings tab below to add this date to your calendar.)

ONCE Profile

Market Cap 4 Billion
ONCE Description

Spark Therapeutics Inc is a United States based company operating in the field of gene therapy. It is focused on debilitating genetic diseases by developing one-time, life-altering treatments. The company's product candidates are in the field of retina-directed gene therapies, liver-directed gene therapies, and central nervous system therapies. The entity's key product, LUXTURNA, is for the treatment of patients with viable retinal cells and confirmed biallelic RPE65 mutation-associated retinal dystrophy. It generates revenue primarily from the license and collaborative agreements.


Visit Website

ONCE Earnings

EPS -1.66 P/E Ratio 0.00
Previous Thu, Aug 8, 2019
Latest Tue, Nov 5, 2019 (In 19 days)

ONCE Dividend

Yield --
Ex-Date --
Pay Date --
History --

ONCE Charts

$34.53
1 Year
$114.20
Dec 26, 2018
Feb 25, 2019


CBPO $115.97 0.52 (0.45%)
China Biologic Products Holdings Inc
NASDAQ: CBPO $4 Billion Mid-Cap. New 52 WEEK HIGH today. Biotech & Pharma industry. 5 Year Return 123%. 1 Year Return 61%. 2019 YTD Return 57%. Earnings in 21 days on Thu, Nov 7. (Use the Earnings tab below to add this date to your calendar.)

CBPO Profile

Market Cap 4 Billion
CBPO Description

China Biologic Products Holdings Inc is a biopharmaceutical company principally engaged in the research, development, manufacturing and sales of human plasma-based products in China. The company operates its business through two majority owned subsidiaries, Shandong Taibang and Guizhou Taibang. China Biologic's product pipeline includes a variety of dosages across multiple product categories. Its principal products are human albumin and immunoglobulin for intravenous injection. All of the company's products are prescription medicines administered in the form of injections. China Biologic's sales model focuses on direct sales to hospitals and inoculation centers and is complemented by distributor sales.


Visit Website

CBPO Earnings

EPS 1.07 P/E Ratio 44.33
Previous Mon, Aug 5, 2019
Latest Thu, Nov 7, 2019 (In 21 days)

CBPO Dividend

Yield --
Ex-Date --
Pay Date --
History --

CBPO Charts

$60.08
1 Year
$116.63
Oct 26, 2018
Today


BPMC $73.62 0.87 (1.17%)
Blueprint Medicines Corp
NASDAQ: BPMC $4 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 290%. 1 Year Return 6%. 2019 YTD Return 44%. Earnings in 12 days on Tue, Oct 29. (Use the Earnings tab below to add this date to your calendar.)

BPMC Profile

Market Cap 4 Billion
BPMC Description

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.


Visit Website

BPMC Earnings

EPS -2.04 P/E Ratio 0.00
Previous Thu, Aug 1, 2019
Latest Tue, Oct 29, 2019 (In 12 days)

BPMC Dividend

Yield --
Ex-Date --
Pay Date --
History --

BPMC Charts

$44.58
1 Year
$102.98
Dec 24, 2018
Jul 25, 2019


FGEN $40.30 1.44 (3.71%)
FibroGen Inc
NASDAQ: FGEN $4 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 83%. 1 Year Return 26%. 2019 YTD Return 12%. Earnings in 28 days on Thu, Nov 14. (Use the Earnings tab below to add this date to your calendar.)

FGEN Profile

Market Cap 4 Billion
FGEN Description

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.


Visit Website

FGEN Earnings

EPS 1.34 P/E Ratio 0.00
Previous Thu, Aug 8, 2019
Latest Thu, Nov 14, 2019 (In 28 days)

FGEN Dividend

Yield --
Ex-Date --
Pay Date --
History --

FGEN Charts

$33.51
1 Year
$61.23
May 10, 2019
Feb 28, 2019


MOR $27.48 0.18 (0.66%)
MorphoSys AG - American Depositary Shares
NASDAQ: MOR $4 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 4%. 1 Year Return 12%. 2019 YTD Return 7%. Earnings in 18 days on Mon, Nov 4. (Use the Earnings tab below to add this date to your calendar.)

MOR Profile

Market Cap 4 Billion
MOR Description

MorphoSys AG is a biotechnology company that develops therapeutic antibodies. The company reports two business segments: partnered discovery and proprietary development. Its partnered discovery segment applies the research, development, and optimization of antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. MorphoSys' profits in this segment stem from successful programs via milestone payments and potential royalties on product sales. In its proprietary development segment, the company develops antibodies that concentrate on inflammatory and autoimmune diseases, as well as cancer and infectious diseases.


Visit Website

MOR Earnings

EPS -0.05 P/E Ratio 0.00
Previous Thu, Aug 8, 2019
Latest Mon, Nov 4, 2019 (In 18 days)

MOR Dividend

Yield --
Ex-Date --
Pay Date --
History --

MOR Charts

$21.75
1 Year
$31.96
Oct 26, 2018
Aug 8, 2019


ALLO $26.37 0.36 (1.38%)
Allogene Therapeutics Inc
NASDAQ: ALLO $4 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 5%. 1 Year Return 11%. 2019 YTD Return 4%. Earnings in 20 days on Wed, Nov 6. (Use the Earnings tab below to add this date to your calendar.)

ALLO Profile

Market Cap 4 Billion
ALLO Description

Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.


Visit Website

ALLO Earnings

EPS -0.41 P/E Ratio 0.00
Previous Wed, Aug 7, 2019
Latest Wed, Nov 6, 2019 (In 20 days)

ALLO Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALLO Charts

$22.20
1 Year
$35.55
Oct 24, 2018
Nov 7, 2018


ALKS $18.23 0.18 (0.98%)
Alkermes PLC
NASDAQ: ALKS $4 Billion Mid-Cap. Biotech & Pharma industry. 5 Year Return 58%. 1 Year Return 55%. 2019 YTD Return 37%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 5 days on Tue, Oct 22. (Use the Earnings tab below to add this date to your calendar.)

ALKS Profile

Market Cap 4 Billion
ALKS Description

Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.


Visit Website

ALKS Earnings

EPS -0.27 P/E Ratio 0.00
Previous Thu, Jul 25, 2019
Latest Tue, Oct 22, 2019 (In 5 days)

ALKS Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALKS Charts

52 Week Low $17.11 set on Thu, Oct 10, 2019
$17.11
1 Year
$42.69
Oct 10, 2019
Oct 29, 2018


NKTR $17.54 0.24 (1.39%)
Nektar Therapeutics
NASDAQ: NKTR $4 Billion Mid-Cap. S&P 500. Biotech & Pharma industry. 5 Year Return 36%. 1 Year Return 65%. 2019 YTD Return 49%. Earnings in 20 days on Wed, Nov 6. (Use the Earnings tab below to add this date to your calendar.)

NKTR Profile

Market Cap 4 Billion
NKTR Description

Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, chronic pain, hemophilia, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.


Visit Website

NKTR Earnings

EPS -0.63 P/E Ratio 8.20
Previous Thu, Aug 8, 2019
Latest Wed, Nov 6, 2019 (In 20 days)

NKTR Dividend

Yield --
Ex-Date --
Pay Date --
History --

NKTR Charts

52 Week Low $15.64 set on Tue, Oct 15, 2019
$15.64
1 Year
$51.28
Oct 15, 2019
Oct 19, 2018


Page 1 of 10


Symbol Price Day Δ YTD Δ
ABBV $74.75 0.34% -16.23%
AGN $170.92 0.45% 25.79%
ALXN $99.51 -5.06% 1.49%
AMGN $203.21 -0.71% 5.89%
BIIB $227.72 0.73% -25.26%
BMRN $67.94 -0.83% -20.03%
BMY $51.51 -0.62% -0.98%
CELG $100.97 0.02% 51.52%
ENDP $4.16 19.20% -46.04%
GILD $65.35 0.08% 3.01%
INCY $78.12 -0.51% 22.91%
JNJ $135.17 1.75% 5.81%
LLY $107.95 -1.60% -6.03%
MNK $2.24 7.69% -86.50%
MRK $84.45 -0.69% 11.72%
MYL $18.74 -0.48% -32.88%
PFE $36.34 -0.44% -15.98%
PRGO $53.93 0.22% 33.16%
REGN $299.40 -1.45% -19.61%
VRTX $176.09 -0.03% 7.32%
ZTS $127.93 -0.61% 51.43%
SHPG $179.20 0.00% 3.76%
NKTR $17.54 1.39% -48.74%
SNY $44.92 1.15% 4.81%
TEVA $6.95 -0.29% -56.15%
ABEO $2.44 -9.96% -65.29%
ABIO $5.32 5.14% -10.44%